


Cdk9 Inhibitor II

09/19

ALTERNATE NAMES: CAY10574; UNII-ZG0O47K626; ZG0O47K626; CAN508; 4-(3,5-Diamino-1H-pyrazol-4-ylazo)-phenol; 4-[(3,5-diamino-1H-pyrazol-4-yl)diazanyl]phenol; 3,5-diamino-4-(4-hydroxyphenyl)azopyrazole; 4-Arylazo-3,5-diamino-1H-pyrazole 31b

CATALOG #: B2903-1 1 mg
B2903-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₉H₁₀N₆O

MOLECULAR WEIGHT: 218.22

CAS NUMBER: 140651-18-9

APPEARANCE: A crystalline solid

PURITY: ≥95%

SOLUBILITY: ~0.5 mg/ml in DMSO and DMF

DESCRIPTION: Cdk9 Inhibitor II is a potent and selective inhibitor of Cdk9 with an IC₅₀ value of 0.35 μM *in vitro*. It is also an inhibitor of Cdk2-cyclin E with respect to ATP, with K_i and IC₅₀ values of 13.3 μM and 20 μM respectively. It reduces the frequency of S-phase cells in the cancer cell line HT-29 and decreases the phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II. It inhibits mRNA synthesis and induces the tumor suppressor protein p53. It inhibits cell proliferation of cancer cell lines such as MCF-7, HOS, G361, and K562 cells with IC₅₀ values of 33 μM, 49 μM, 64 μM, and 62 μM respectively.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Krystof, V., Cankar, P., Frysová, I., et al. 4-Arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. *Journal of Medicinal Chemistry* 49, 6500-6509 (2006).

RELATED PRODUCTS:

ABC-1183 (Cat. No. B2221)
 PHA-767491(HCl) (Cat. No. B1639)
 Dinaciclib (Cat. No. 9537)
 AZD-5438 (Cat. No. B2073)
 Riviciclib hydrochloride (Cat. No. B2567)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**